Allarity Therapeutics Outlines Company's 2024 Progress and Objectives

  Current Cash Balance of $20 million Expected to Provide Runway Into 2026Allarity to Pause Use of ATMCap Table Successfully Cleaned UpAllarity's Stenoparib Shows Extended Duration of Phase 2 Clinical Benefit Boston (July 22, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today outlines the Company's progress in 2024 and future objectives. Led by New Management Allarity has ...